Abstract
A 55 years old male patient, who is planned for bronchoscopy developed central anti-cholinergic syndrome due to therapeutic dose of atropine. Withdrawal of atropine has improved the symptoms. Thereafter, instillation of atropine as eye drops leads to reappearance of symptoms. The reaction was definite according to Naranjo’s algorithm. It was severe and definitely preventable according to Modified Hartwig and Siegel’s scale and Modified Schumock and Thornton scale respectively. Central anti-cholinergic syndrome may be due to variation in the genetic susceptibility (Idiosyncrasy) to atropine. Idiosyncratic reaction on administration of atropine as a pre-anesthetic medication or eye drops should be kept in mind while prescribing.
Keywords: Adverse drug reaction, Anti-cholinergic drugs, Atropine, Central anti-cholinergic syndrome, Pre-anesthetic medication, Eye drops
Current Drug Safety
Title:Central Anti-Cholinergic Syndrome Induced by Single Therapeutic Dose of Atropine
Volume: 7 Issue: 1
Author(s): Ashwin Panchasara, Divyesh Mandavia, Ashish P. Anovadiya and C. B. Tripathi
Affiliation:
Keywords: Adverse drug reaction, Anti-cholinergic drugs, Atropine, Central anti-cholinergic syndrome, Pre-anesthetic medication, Eye drops
Abstract: A 55 years old male patient, who is planned for bronchoscopy developed central anti-cholinergic syndrome due to therapeutic dose of atropine. Withdrawal of atropine has improved the symptoms. Thereafter, instillation of atropine as eye drops leads to reappearance of symptoms. The reaction was definite according to Naranjo’s algorithm. It was severe and definitely preventable according to Modified Hartwig and Siegel’s scale and Modified Schumock and Thornton scale respectively. Central anti-cholinergic syndrome may be due to variation in the genetic susceptibility (Idiosyncrasy) to atropine. Idiosyncratic reaction on administration of atropine as a pre-anesthetic medication or eye drops should be kept in mind while prescribing.
Export Options
About this article
Cite this article as:
Panchasara Ashwin, Mandavia Divyesh, P. Anovadiya Ashish and B. Tripathi C., Central Anti-Cholinergic Syndrome Induced by Single Therapeutic Dose of Atropine, Current Drug Safety 2012; 7 (1) . https://dx.doi.org/10.2174/157488612800492799
DOI https://dx.doi.org/10.2174/157488612800492799 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PET Imaging of Adenosine Receptors in Diseases
Current Topics in Medicinal Chemistry Formulation Strategies of Nano Lipid Carrier for Effective Brain Targeting of Anti-AD Drugs
Current Pharmaceutical Design Differences in Relative Levels of 88 microRNAs in Various Regions of the Normal Adult Human Brain
MicroRNA Substituted Aminobenzothiazole Derivatives of Tacrine: Synthesis and Study on Learning and Memory Impairment in Scopolamine-Induced Model of Amnesia in Rat
Mini-Reviews in Medicinal Chemistry A Comprehensive Investigation of Molecular Signatures and Pathways Linking Alzheimer’s Disease and Epilepsy <i>via</i> Bioinformatic Approaches
Current Alzheimer Research The Large Conductance Calcium- and Voltage-activated Potassium Channel (BK) and Epilepsy
CNS & Neurological Disorders - Drug Targets Potential Health Benefits of Passion Fruit Peel Flour
The Natural Products Journal 2-Arylindoles: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activity
Current Medicinal Chemistry Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Potential Therapeutic Role of Carnitine and Acetylcarnitine in Neurological Disorders
Current Pharmaceutical Design Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Current Pharmaceutical Biotechnology Endoplasmic Reticulum Protein Quality Control in Neurodegenerative Disease: The Good, the Bad and the Therapy
Current Medicinal Chemistry Clinical Trials for Neuroprotection in ALS
CNS & Neurological Disorders - Drug Targets Editorial: Advances in the Treatment of Neurodegenerative Diseases and Epilepsy
Current Pharmaceutical Design Cardiac Monitoring in Patients with Syncope: Making that Elusive Diagnosis
Current Cardiology Reviews Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis
CNS & Neurological Disorders - Drug Targets Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Polyphenols and Neuroprotection against Ischemia and Neurodegeneration
Mini-Reviews in Medicinal Chemistry Treating Asthma as a Neuroelectrical Disorder
Inflammation & Allergy - Drug Targets (Discontinued)